Saint Noble Medical-B (02257.HK) will hold a Board of Directors meeting on March 27 to approve the annual performance.

Gelonghui, March 17th丨Saint诺医药-B (02257.HK) announced that the Board of Directors meeting will be held on March 27, 2025, to approve the release of the annual performance announcement of the company and its subsidiaries for the year ending December 31, 2024.

Gelonghui FinanceMar 17 17:04

SIRNAOMICS-B: NOTICE OF BOARD MEETING

HKEXMar 17 17:00 · Announcements

All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?

The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.

Securities TimesMar 13 09:50

The Hong Kong stock market for Medical stocks is surging! In February, the strongest has risen over 220%, what happened?

Recently, the General Office of the State Council forwarded the "2025 Action Plan for Stabilizing Foreign Investment" from the Ministry of Commerce and the National Development and Reform Commission, promoting the orderly opening of the Biomedical sector.

Futu NewsFeb 27 14:58

Saint Noble Pharmaceutical-B (02257): Cheng Hai has been appointed as a member of the Audit Committee.

Saint Noble Pharmaceuticals-B (02257) announced that Chang Hai has been appointed as the independent non-executive Director of the company to review...

Zhitong FinanceFeb 19 17:01

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 8 09:59